BDMD vs. TLSI, INGN, NNOX, CVRX, NYXH, CV, SKIN, INFU, ELMD, and BSGM
Should you be buying Baird Medical Investment stock or one of its competitors? The main competitors of Baird Medical Investment include TriSalus Life Sciences (TLSI), Inogen (INGN), Nano-X Imaging (NNOX), CVRx (CVRX), Nyxoah (NYXH), CapsoVision (CV), Beauty Health (SKIN), InfuSystem (INFU), Electromed (ELMD), and Biosig Technologies (BSGM). These companies are all part of the "medical equipment" industry.
Baird Medical Investment vs. Its Competitors
Baird Medical Investment (NASDAQ:BDMD) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.
Baird Medical Investment has a beta of -1.01, indicating that its stock price is 201% less volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500.
Baird Medical Investment has higher earnings, but lower revenue than TriSalus Life Sciences.
TriSalus Life Sciences has a consensus target price of $10.90, suggesting a potential upside of 129.47%. Given TriSalus Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe TriSalus Life Sciences is more favorable than Baird Medical Investment.
In the previous week, TriSalus Life Sciences had 1 more articles in the media than Baird Medical Investment. MarketBeat recorded 4 mentions for TriSalus Life Sciences and 3 mentions for Baird Medical Investment. TriSalus Life Sciences' average media sentiment score of 0.77 beat Baird Medical Investment's score of 0.62 indicating that TriSalus Life Sciences is being referred to more favorably in the news media.
19.8% of Baird Medical Investment shares are held by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are held by institutional investors. 78.9% of Baird Medical Investment shares are held by insiders. Comparatively, 27.5% of TriSalus Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Baird Medical Investment has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -86.61%.
Summary
TriSalus Life Sciences beats Baird Medical Investment on 8 of the 12 factors compared between the two stocks.
Get Baird Medical Investment News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BDMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Baird Medical Investment Competitors List
Related Companies and Tools
This page (NASDAQ:BDMD) was last updated on 10/16/2025 by MarketBeat.com Staff
